# Inferior vena cava anomalous drainage into the left atrium with severe pulmonary arterial hypertension: a case report and review of management strategies

**Authors:** Lei Yang, Lishi Shao, Feifei Zhou, Yongju Yang, Guifang Sun, Bin Liu

PMC · DOI: 10.3389/fcvm.2025.1635559 · Frontiers in Cardiovascular Medicine · 2026-01-12

## TL;DR

A rare case of abnormal blood vessel drainage into the heart is managed with targeted therapy, showing symptom improvement.

## Contribution

Presents a novel combined treatment approach for IVC anomaly with pulmonary hypertension.

## Key findings

- Combined 'treat and repair' strategy improved symptoms and reduced pulmonary artery pressure.
- Case highlights diagnostic and therapeutic challenges in managing IVC anomalies with PH.
- Multidisciplinary consultation was key to successful management of complex cardiovascular disorder.

## Abstract

Anomalous drainage of the inferior vena cava (IVC) into the left atrium is a rare congenital anomaly seldom associated with pulmonary arterial hypertension (PAH). This condition may correlate with atrial septal defect (ASD), pulmonary arteriovenous fistula, and chronic hypoxemia. We present a case of a 34-year-old female admitted with recurrent chest tightness, dyspnea, and palpitations. Comprehensive evaluations, including transthoracic echocardiography, computed tomography angiography, and right heart catheterization, confirmed the diagnosis of IVC anomalous drainage into the left atrium complicated by ASD (about 3 cm), right inferior pulmonary vein anomalous drainage into the inferior vena cava, and severe PAH. Following multidisciplinary consultation, a combined “treat and repair” strategy was adopted, initiating targeted PAH therapy with ambrisentan and sildenafil. At the 3-month follow-up, the patient reported significant symptomatic improvement, resumed daily physical activities without cardiorespiratory discomfort, PASP decreased from 146 mmHg to 127 mmHg and demonstrated enhanced functional capacity. This case highlights the diagnostic challenges and therapeutic considerations for IVC anomalies associated with PH, contributing novel insights to the management of complex congenital cardiovascular disorders.

## Linked entities

- **Chemicals:** ambrisentan (PubChem CID 197712), sildenafil (PubChem CID 135398744)
- **Diseases:** pulmonary arterial hypertension (MONDO:0015924), atrial septal defect (MONDO:0006664), pulmonary hypertension (MONDO:0005149)

## Full-text entities

- **Diseases:** congenital cardiovascular disorders (MESH:D018376), ASD (MESH:D006344), dyspnea (MESH:D004417), pulmonary arteriovenous fistula (MESH:C562404), palpitations (MESH:D006331), PAH (MESH:D000081029), congenital anomaly (MESH:D000013), IVC anomalies (MESH:C563013), chronic hypoxemia (MESH:D000860), chest tightness (MESH:D002637)
- **Chemicals:** sildenafil (MESH:D000068677), ambrisentan (MESH:C467894)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12833240/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12833240/full.md

## References

18 references — full list in the complete paper: https://tomesphere.com/paper/PMC12833240/full.md

---
Source: https://tomesphere.com/paper/PMC12833240